司库奇尤单抗治疗16例银屑病关节炎临床疗效及安全性观察  

Clinical Efficacy and Safety of Secukinumab for the Treatment of 16 Cases of Psoriatic Arthritis

作　　者：盛宇俊[1] 黄贺[1] 蔡明龙 袁涛 李蔚然[1] 张学军[1] SHENG Yujun;HUANG He;CAI Minglong;YUAN Tao;LI Weiran;ZHANG Xuejun(Department of Dermatology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China)

机构地区：[1]安徽医科大学第一附属医院皮肤性病科,安徽合肥230022

出　　处：《中国皮肤性病学杂志》2021年第11期1325-1328,共4页The Chinese Journal of Dermatovenereology

基　　金：国家自然科学基金面上项目(81872527)。

摘　　要：目的观察司库奇尤单抗治疗银屑病关节炎临床疗效及安全性。方法在安徽医科大学第一附属医院就诊的银屑病伴关节炎患者16例,给予司库奇尤单抗皮下注射治疗,初始剂量300 mg,在第0、1、2、3、4、8、12周给予300 mg/次,以后每4周注射1次,总共16周的治疗观察周期,主要终点指标是第16周时美国风湿病学会(ACR)有关类风湿关节炎改善的达到ACR20比例作为评价指标,同时记录患者银屑病皮损面积和严重度指数(PASI)改变,观察药物疗效及药物不良反应。结果16例患者至少接受16周治疗周期的药物治疗,第16周时,有9例达到ACR20评分,有6例到ACR50评分;第16周时,达到PASI75、90、100的分别为93.75%、87.50%和56.25%。所有患者均未出现严重的不良反应,4例出现瘙痒,3例出现荨麻疹。结论司库奇尤单抗治疗银屑病关节炎疗效较为显著,不良反应较少,为银屑病关节患者提供新的治疗选择。Objective To evaluate the clinical efficacy and safety of secukinumab in the treatment of psoriatic arthritis.Methods Sixteen patients with psoriatic arthritis in the First Affiliated Hospital of Anhui Medical University were given subcutaneous injection of secukinumab at a dose of 300 mg at week 0,1,2,3,4,8,12,followed by injection every four weeks for a total of 16 weeks of treatment observation period.The main endpoint indicator is the proportion of ACR20 related to the improvement of rheumatoid arthritis by the American College of Rheumatology(ACR)at week 16.As an evaluation index,the patient′s psoriasis area and severity index(PASI)changes were recorded at the same time,and the drug efficacy and drug adverse reactions were observed.Results Sixteen patients received at least 16 weeks treatment.At week 16,nine patients achieved ACR20 score and six patients achieved ACR50 score.By week 16,PASI 75,PASI 90,and PASI 100 were achieved in 93.75%,87.50%,and 56.25%of patients,respectively.No serious adverse reactions occurred in all patients,itching occurred in 5 patients,and urticaria occurred in four patients.Conclusion The treatment of psoriatic arthritis with secukinumab is more effective and has fewer adverse reactions,providing new treatment options for patients with psoriatic arthritis.

关 键 词：银屑病 关节炎 司库奇尤单抗 临床疗效 安全性 

分 类 号：R758.63[医药卫生—皮肤病学与性病学] R684.3[医药卫生—临床医学]